Amferia closes investment round for 1.2 million euros

Swedish medtech company Amferia receives investment to advance development of antimicrobial solutions and commercialize first products in veterinary medicine

Mölndal, Sweden, September 3, 2024 - Swedish medtech company Amferia has closed an investment of EUR 1.2 million. The financing round was oversubscribed and supported by existing owners as well as several new investors, including Chalmers Ventures. Amferia will use the fresh capital to advance its clinical development in the field of human medicine and expand the commercialization of its technologies.

Innovative solutions against resistant bacteria

Amferia develops innovative antimicrobial solutions based on a proprietary platform. This technology uses antimicrobial peptides to fight bacterial infections. The company recently signed its first commercial agreement with Orkla Wound Care to commercialize a wound patch for animals that is also effective against resistant bacteria.

New ways to fight infections

According to Anand Rajasekharan, CEO and co-founder of Amferia, the number of deaths from bacterial infections could surpass those from cancer and heart disease in the future.

Our hydrogel technology enables the safe use of antimicrobial peptides that target bacteria without damaging the surrounding tissue. We mimic the immune system and reduce the need for antibiotics,

Anand Rajasekharan, CEO and co-founder of Amferia

The investment will help Amferia to develop further products for the human market. These are intended to help patients who are at increased risk of skin and wound infections, including those caused by resistant bacteria. However, Amferia's first market entry will be in the area of animal health, where a new wound plaster will be launched.

Opportunities for the future

Jonas Bergman, Investment Director at Chalmers Ventures, sees great potential in the technology.

This investment will help Amferia to further develop its hydrogel platform and bring it to market for human use. Part of the funds will be invested in regulatory work to enable a smooth market launch.

Jonas Bergman, Investment Director at Chalmers Ventures

Amferia's approach offers a new way to use antimicrobial peptides in a stable and effective way. These peptides destroy bacteria through their positive charge, which attracts the negatively charged bacteria and destroys their membranes. Amferia's patented hydrogel platform protects the peptides from enzymatic degradation, making them particularly effective - even against resistant bacteria.